Introduction
Acute kidney injury (AKI) is a serious clinical problem for critically ill patients and characteristically portends an increase in morbidity and mortality [1] . Epidemiologic studies have shown the incidence of AKI is increasing, and mortality has only marginally improved and remains unacceptably high [2 ] .
This poor outcome still occurs despite significant advances in our understanding of the pathophysiology of AKI and in overall supportive care for critically ill patients with AKI. Moreover, several therapeutic interventions have shown remarkable promise in animal models of AKI. Translational evidence in humans, however, has been notably absent and disappointing.
One plausible explanation for this apparent lack of progress is a paucity of sensitive biomarkers capable of detecting kidney injury early in the development of AKI. This has likely translated into a significant interval from the actual time of kidney insult to the clinical detection of AKI. As a consequence, this delay in diagnosis could be considered a missed opportunity for early therapeutic intervention before injury becomes more established. Moreover, the absence of biomarkers for early detection of AKI has been suggested to have had a negative impact on large clinical trials of potentially promising interventions for AKI [3, 4] .
The early detection of AKI has both physiologic and clinical sensibility. The earlier an injurious process to the kidney can be identified, the more timely additional preventive (i.e. removal of stimulus for injury) and potential therapeutic measures [i.e. renal replacement therapy (RRT) [5 ] ] can be initiated.
Herein, we review the early diagnosis of AKI. We highlight the limitations to our current methods for diagnosis and further expand our discussion to several novel biomarkers with great promise for improving the care of the critically ill patient with AKI.
The ideal biomarker of acute kidney injury
An ideal biomarker for detecting AKI for use in clinical practice would ideally encompass several characteristics [6] . First, it would be easy, rapid and inexpensive to measure and use readily available specimens (i.e. urine, serum). Second, it would be precise and reliable and use standardized assay methods easily applied at the bedside. Third, it would be highly sensitive for AKI to permit early detection. Moreover, it would enable monitoring of the course of injury patterns over time and have some ability to predict the severity and trajectory of AKI (i.e. need for RRT). Finally, it would be specific, in order to aid in the discrimination and classification of subtypes of AKI.
There would be tremendous value to biomarkers capable of discriminating the underlying precipitant and etiologies of AKI, for example, variable expression in conditions associated with cardiopulmonary bypass, sepsis, ischemia, or toxin-mediated AKI or differentiation of AKI and chronic kidney disease (CKD). Regrettably, no single biomarker will ever fulfill all these ideal conditions. Rather, there is some suggestion that a combination of biomarkers for AKI will be developed that may include aspects of all these characteristics.
Limitations to conventional measures of kidney function
The diagnosis of AKI, at present, largely depends on the detection of changes in endogenous surrogate markers of kidney function, specifically serum creatinine (SCr) and urea and other urinary tests. Regrettably, these markers are not ideal, each has limitations and none reflect genuine kidney injury. They are rather surrogates for altered function.
Serum creatinine
Serum creatinine is an amino acid compound derived from the metabolism of creatine in skeletal muscle and from dietary meat intake. Creatinine has a molecular weight of 113 Da, is released into the plasma at a relatively constant rate, is freely filtered by the glomerulus, and is not reabsorbed or metabolized by the kidney. Accordingly, the clearance of SCr is the most widely used means for estimating glomerular filtration rate (GFR) and SCr levels generally have an inverse relationship to GFR [7] . Thus, a rise in SCr is associated with a corresponding decrease in GFR and generally implies a reduction in kidney function and vice versa. There are limitations, however, with the use of SCr as a serum marker to estimate GFR. First, an estimated 10-40% of creatinine clearance occurs by tubular secretion of SCr into the urine [8] . This effect can potentially mask a significant initial decline in GFR. 
Serum urea
Serum urea is a water-soluble, low molecular weight by-product of protein metabolism that is used as a serum marker of uremic solute retention and elimination. For chronic hemodialysis patients, the degree of urea clearance has clearly shown correlation with clinical outcome and is used to model hemodialysis adequacy over time.
Acute and large rises in serum urea concentration are characteristic of the development of the uremic syndrome and retention of a large variety of uremic toxins. In addition, the accumulation of urea itself is believed to predispose to adverse metabolic, biochemical and physiological effects such as increased oxidative stress, altered function of Na þ /K þ /Cl À cotransport pathways important in regulation of intracellular potassium and water, and alterations in immune function [9, 10] . Similar to SCr, urea exhibits a nonlinear and inverse relationship with GFR. The use of urea to estimate GFR, however, is problematic due to the numerous extra-renal factors that influence its endogenous production and renal clearance, independent of GFR. First, the rate of urea production is not constant. Urea can be grossly modified by a high protein intake, critical illness (i.e. sepsis, burns, trauma), gastrointestinal hemorrhage, or drug therapy such as use of corticosteroids or tetracycline. Conversely, patients with chronic liver disease and low protein intake can have lower urea levels without noticeable changes in GFR. Second, the rate of renal clearance of urea is not constant. An estimated 40-50% of filtered urea is passively reabsorbed by proximal renal tubular cells. Moreover, in states of decreased effective circulating volume (i.e. volume depletion, low cardiac output), there is enhanced reabsorption of sodium and water in the proximal renal tubular cells along with a corresponding increase in urea reabsorption. Consequently, the serum urea concentration may increase out of proportion with changes in SCr and be underrepresentative of GFR.
Urine output
Urine output is routinely measured in critically ill patients. Trends in urine volume can be helpful in that continuous output can be used as a dynamic gauge of kidney function. Urine output may be a sensitive barometer for changes in kidney perfusion, however urine output in general lacks sensitivity and specificity for AKI. Even patients with severe AKI, characterized by markedly elevated SCr, can still maintain a normal or elevated urine output.
Traditional urinary biochemistry
Numerous tests of urinary biochemistry (i.e. fractional excretion of sodium, fractional excretion of urea) have been described and traditionally used to aid clinicians in the detection and classification of early AKI, in particular into so-called prerenal azotemia (PRA) and acute tubular necrosis (ATN) [11, 12] . Regrettably, these tests also lack sensitivity and specificity for the early characterization of AKI [13] . Moreover, these tests remain unproven and questionable in critically ill patients who often receive massive fluid resuscitation, diuretics, vasopressor infusions, radiocontrast media, and nephrotoxic drugs. These traditional measures of urinary biochemistry have no value for providing a quantitative measure of kidney injury or any useful prognostic information. Finally, it is fundamental that clinicians recognize that the classification of AKI into so-called PRA and ATN is totally arbitrary, that these likely exist on a continuum of injury, and their separation in diagnostic terms also has limited clinical implications and prognostic value.
Proteinuria
Urinary excretion of protein has been described in numerous studies of AKI [14] [15] [16] [17] [18] and is frequently detected in the urine of critically ill patients [19] . In a cohort of 104 critically ill patients, most with AKI or acute on CKD admitted to a medical ICU, 69% had evidence of microalbuminuria (<300 mg/g creatinine) or proteinuria (!300 mg/g creatinine) on spot urine testing at the time of admission [19] . Urinary protein detection was more common in elderly patients, those with diabetes, CKD and shock. Moreover, a high albumin-to-creatinine ratio (!100 mg/g) was associated with a significant increased adjusted odds of death (odds ratio 2.7; 95% confidence interval 1.1-7.2; P ¼ 0.04). This finding has similarly been shown in larger cohorts of mixed medical/surgical ICU patients [20, 21] . The early detection of microalbuminuria, suggestive as a marker of increased capillary permeability to proteins [22] , may yield predictive and prognostic value for illness severity and mortality. Regrettably, no studies have yet evaluated the value of microalbuminuria for predicting or in the early diagnosis of AKI in this population [23] . Detection of low molecular weight proteinuria of tubular origin has also been described in a cohort of critically ill patients with septic AKI [17] . The detection of urinary a 1 -microglobulin was found to predict need for RRT in a small cohort of patients with AKI, however few of these patients were critically ill [18] . Overall, no studies have a priori assessed for urinary protein excretion as a diagnostic tool for early AKI or for projection of subsequent kidney function in critically ill patients.
Urinary sediment and microscopy
The urinary sediment on microscopy has traditionally been used to discriminate the severity of AKI (i.e. differentiate PRA from established AKI or ATN). The classical urinary profile in ATN contains renal tubular epithelial cells with coarse granular, muddy brown or mixed cellular casts, whereas the sediment in PRA is rather bland and may show occasional hyaline or fine granular casts. Examination of the urinary sediment may have value in critically ill patients, in particular when there is suspicion of systemic vasculitis, acute or rapidly progressive glomerulonephritis or pulmonary-renal syndromes. In these circumstances, the detection of dysmorphic red blood cells (RBCs) or RBC casts may have important diagnostic, prognostic and therapeutic value. Few studies have described the urinary sediment in critically ill patients with AKI. Moreover, the value of the urinary sediment in classifying the etiology and severity of AKI is imperfect and often fails to correlate with urinary biochemistry or derived indices [13] . Regrettably, descriptions of the urinary sediment in critically ill patients with AKI have been highly variable due to inconsistencies in the timing of measurement, the duration of AKI and the underlying pathophysiology predisposing to AKI. There have been no clinical studies to date that have a priori evaluated the value of the urinary sediment and microscopy for the early detection of AKI.
Novel biomarkers of acute kidney injury
There are a number of serum and urine biomarkers that are currently being investigated and validated for the early diagnosis of AKI. New and innovative technologies using animal and human genomics, proteomics and microarray analysis have enabled the discovery of a spectrum of new potential biomarkers. This article will focus on a few of the most developed and promising emerging biomarkers of AKI for use in clinical practice, specifically cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) ( Table 1 ). These biomarkers are likely heterogeneous in their expression (i.e. severity of insult, timing of detection, duration of detection, various etiologies). As a consequence, there has been a suggestion that these biomarkers should be incorporated into an 'AKI panel' of biomarkers that will hopefully yield reliable methods for detecting, distinguishing, classifying and predicting the clinical course of AKI across a range of clinical presentations.
Serum cystatin C
Cystatin C is an endogenous cysteine proteinase inhibitor of low molecular weight. It holds many ideal features for use as a surrogate marker of kidney function and estimate of GFR and has been shown superior to serum creatinine [24, 25] . Cystatin C is synthesized at a relatively constant rate and released into plasma by all nucleated cells in the body [18, 26, 27] . It is reportedly not significantly affected by patient age, sex, muscle mass or changes in diet. In a large cross-sectional study of 8058 patients, however, several factors were found to be associated with an elevated cystatin C, including older age, male sex, greater height, greater weight, current smoking status, and elevated C-reactive protein levels [28] . Cystatin C levels have also been found to be influenced by abnormal thyroid function, use of immunosuppressive therapy (i.e. corticosteroids) and the presence of systemic inflammation [28] [29] [30] [31] .
Nonetheless, the main catabolic site of cystatin C is the kidney, with more than 99% freely filtered by the glomerulus. Cystatin C is not notably secreted or reabsorbed; however, it is nearly completely metabolized by proximal renal tubular cells. As a consequence, there is little to no detectable cystatin C present in the urine. Thus, while a reduction in GFR correlates well with a rise in serum cystatin C level, true clearance of cystatin C cannot be determined. Serum cystatin C concentrations have demonstrated good inverse correlations with radionuclide derived measurements of GFR [32, 33] .
The diagnostic value of cystatin C as an estimate of GFR has now been investigated in multiple clinical studies [32] [33] [34] . There is a suggestion that cystatin C-based estimates of GFR may perform better in selected patient populations, in particular those with lower SCr concentrations such as elderly patients, children, renal transplant recipients, cirrhotics, and those that are malnourished [35, 36] . In addition, serum cystatin C may be more sensitive to early and mild changes of kidney function compared with creatinine [24, 37] . In a small cohort study of critically ill patients, elevation in serum cystatin C consistent with AKI, defined by at least a 50% increase from baseline, was evident 1-2 days prior to changes in SCr [27] .
Serum cystatin C is now increasingly becoming more available due to the development of standardized immunonephelometric assays that can provide rapid results and incorporate this measurement into routine clinical practice.
Urinary cystatin C
Cystatin C has also been detected in the urine in AKI and has been suggested as an additional tool for quantifying the severity of tubular injury [32, 38 ] . In a small prospective study of critically ill patients with AKI, elevated urinary cystatin C was highly predictive of subsequent need for acute RRT and outperformed several other urinary biomarkers [18] .
Kidney injury molecule-1
KIM-1 is a type 1 transmembrane glycoprotein that is normally minimally expressed in kidney tissue. It shows, however, marked upregulation in proximal renal tubular cells in response to ischemic or nephrotoxic AKI [39, 40, 41 ]. The ectodomain segment of KIM-1 is shed from proximal cells and detected in the urine by immunoassay [26] . Kidney biopsies from patients with AKI show increased and significantly greater KIM-1 tissue expression compared with other acute and chronic kidney diseases (i.e. urinary tract infection, contrast nephropathy, postrenal disease) [26] . In addition, urinary levels of KIM-1 were significantly higher in established AKI compared with other causes of AKI (i.e. PRA, contrast-induced nephropathy) or CKD. Thus, KIM-1 may represent an early, noninvasive biomarker for proximal tubular AKI.
Recently, urinary KIM-1 along with N-acetyl-b-(D)-glucosaminidase activity (NAG) were evaluated in a prospective study of 201 hospitalized patients with AKI [42 ] . Both urinary KIM-1 and NAG showed increasing trends with increasing severity of illness as assessed by Acute Physiology, Age, Chronic Health Evaluation (APACHE) II and multiple organ failure scores. For this study, urinary KIM-1 and NAG values were arbitrarily stratified into quartiles. When compared with patients in the lowest quartile, those in higher quartiles showed significant and step-like increases in the odds for both RRT and hospital death, suggesting these Early diagnosis of acute kidney injury Bagshaw and Bellomo 641 biomarkers have some predictive ability for clinical outcomes in patients with AKI.
Additional prospective studies in AKI are currently being performed that will hopefully expand our understanding of the clinical value of KIM-1 in the early diagnosis and management of AKI.
Neutrophil gelatinase-associated lipocalin NGAL belongs to the lipocalin superfamily of over 20 structurally related secreted proteins and is thought to participate in ligand transport with a b-barreled calyx [43] . Human NGAL was originally isolated as a 25 kDa protein covalently bound to gelatinase from human neutrophils and was shown to be markedly upregulated in response to kidney ischemic or nephrotoxic injury [43, 44] . These early results suggest that NGAL may be an early and sensitive urinary biomarker of ischemic and nephrotoxic AKI.
Early elevations in urinary NGAL after kidney transplantation have been shown to be predictive of delayed graft failure, trajectories in serum creatinine and need for RRT during the first week following transplantation [45, 46 ] .
Urinary NGAL has also been examined in patients undergoing cardiac surgery with cardiopulmonary bypass [46 ,47,48 ] . In a small cohort of children undergoing cardiopulmonary bypass, detectable increases in urinary and serum NGAL were evident within 2 h after surgery and highly predictive of subsequent AKI in the following 1-3 days [46 ] (Fig. 1) . For example, a threshold urinary NGAL value of at least 50 mg/l detected at 2 h after surgery had a sensitivity of 100% and specificity of 98% for a diagnosis of AKI 1-3 days later, conventionally defined as an increase in SCr of at least 50% from baseline. Similar postoperative increases in urinary IL-18 have now been shown in adult patients undergoing elective cardiopulmonary bypass [48 ] . Interestingly, in this study, all patients had abnormally elevated urinary NGAL values immediately following surgery. Those patients who subsequently developed AKI, defined again by an increase in SCr of at least 50% from baseline, however, showed persistent and increasing values in the ensuing 3 h, whereas in those not developing AKI, urinary NGAL values started to fall by 1 h. Moreover, for those with AKI, SCr was no different from preoperative baseline levels at 24 h and did not peak until postoperative day 4. This study reported urinary NGAL values of at least 213 ng/ml at 18 h had the best operative characteristics (area under the receiver operating characteristics curve 80%).
Recently, urinary NGAL has been evaluated to predict contrast nephropathy in cardiac catheterization and interventions [49 ,50] . In a cohort of 35 patients receiving elective percutaneous coronary interventions, serum and urine NGAL values showed modest but significant increases at 2-4 and 4-12 h after contrast exposure prior to returning to baseline [49 ] . Of note, there were no significant changes to SCr at 24 and 48 h. Interestingly, patients with diabetes mellitus had significantly higher baseline serum NGAL values than those without the condition. This small study has shown the potential value of NGAL in detecting kidney injury after contrast media, however additional study is warranted.
Overall, several studies are in the process of evaluating the role of NGAL in the diagnosis and management of AKI. These studies, coupled with those of other biomarkers, will soon be reported and greatly add to our current understanding of their value for patients at risk for AKI.
Urinary interleukin-18
Numerous cytokines have now been detected in the urine of critically ill patients with AKI including IL-1, IL-6, IL-8, IL-18, tumor necrosis factor-a, and platelet activating factor (PAF) [26, [51] [52] [53] . Inflammatory states characterized by increased production of these cytokines may be both a consequence of and predispose to AKI. In one series of 40 patients undergoing kidney transplant, urinary IL-6, IL-8 and actin were found to be elevated and predictive of early and sustained postoperative acute renal failure (ARF) [54] . In another small series, increased PAF was detected in the urine of patients with septic ARF [55] . Perhaps the best characterized cytokine in AKI, however, is urinary IL-18. Experimental studies have shown IL-18, a proinflammatory cytokine and likely mediator of tubular injury, can be induced in the proximal tubule and detected in the urine in ischemic AKI [56] .
IL-18 was found significantly increased in the urine of patients with established AKI when compared with urine from those with PRA, urinary tract infection, CKD or healthy controls [57] . In addition, raised urinary IL-18 concentrations early after kidney transplantation have been shown as predictive of delayed graft failure [57, 58 ] .
In a small pilot study of patients receiving cardiac surgery with cardiopulmonary bypass, IL-18 was detected within 4-6 h after surgery and peaked at about 12 h for those subsequently developing AKI (Fig. 1) . Moreover, when AKI was defined conventionally as an increase of at least 50% in SCr, AKI was not detected until approximately 48-72 h after bypass [46 ] . In addition, the early postoperative increases in IL-18 were found to have predictive ability for the future development of AKI at 24 h (area under the receiver operating characteristics curve 73%). Similarly, elevated urinary IL-18 at 4 h after surgery was correlated with the duration of AKI and renal recovery, defined by the number of days required for SCr to fall to below the 50% increase in baseline.
Recently, in a nested case-control study of critically ill patients with acute respiratory distress syndrome (ARDS), elevated urinary IL-18 values preceded clinical evidence of overt AKI, defined by an increase of at least 50% in SCr by an estimated 24-48 h [59] . Urinary IL-18 values of at least 100 pg/ml were associated with an estimated 6.5 increased odds of developing AKI within 24 h. Moreover, in these ARDS patients, a high urinary IL-18 concentration at enrolment was shown to independently predict death.
Conclusion
The early detection of AKI is now a recognized clinical and research priority. The novel biomarkers discussed in this review potentially have great promise for improving the dismal prognosis for critically ill patients with AKI by principally allowing for earlier detection of injury. There are now novel biomarkers both for the detection of changes to glomerular filtration and tubular injury. The hope is that these biomarkers will collectively represent a novel tool for early noninvasive diagnosis, risk stratification, classification of severity, and prognosis in AKI.
It should be highlighted, however, that these biomarkers are early in their clinical application, are not yet all widely available and have not been assessed in large multicenter prospective studies that will most certainly provide the sufficient statistical power to correlate with clinically important and patient-centered outcomes, such as need for RRT and renal recovery. In addition to these large prospective studies, these biomarkers also need to be further characterized in select populations (i.e. sepsis) which may be stratified and may be shown to benefit more from targeted interventions.
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